13.3 million shares were issued for listing at a price of 16 US dollars, with the stock code of “cvac” and the financing amount of US $200 million. Bank of America Securities, Jeffrey and
curevac were founded in 2000, and their products include cv8102 and cv7202. At present, cv8102 is in the first phase of solid tumor trials, and cv7202 is in the first phase of rabies vaccine trial. The company is also pushing ahead with its mRNA vaccine program for the new coronavirus, which started a phase of trials in healthy volunteers in June this year, and the results are expected to be available in the fourth quarter of 2020.
curevac said in a regulatory document that the proceeds from the IPO would fund its new crown vaccine program and manufacturing capacity. The company is trying to expand capacity through a new manufacturing plant in Germany, which will be able to produce billions of doses of vaccine.
curevac’s chief executive said on Friday that curevac was in discussions with major pharmaceutical companies to establish a partnership to help promote and sell its new crown vaccine.
in June this year, the German government announced the injection of 300 million euro into curevac, so as to obtain a 23% stake in the company, so as to prevent the company from being acquired by the United States.
the British pharmaceutical giant GlaxoSmithKline also announced in July that it would inject 130 million pounds into curevac and acquire nearly 10% of the company’s shares. Under its agreement with GlaxoSmithKline, the company will be eligible for development and regulatory milestone payments of up to 277 million pounds, commercial milestone payments of up to 329 million pounds, and graded royalties on the sale of products.